// App-Quantinova.ai

LB1902 : FIXED-DURATION IBRUTINIB AND VENETOCLAX (I+V) VERSUS CHLORAMBUCIL PLUS OBINUTUZUMAB (CLB+O) FOR FIRST-LINE (1L) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRIMARY ANALYSIS OF THE PHASE 3 GLOW STUDY

Researchers

Presenter

  • Arnon Kater

Principal Investigators

  • Carol Moreno

  • George Follows

  • Talha Munir

  • Mark-David Levin

  • Ohad Benjamini

  • Ann Janssens

  • Anders Osterborg

  • Tadeusz Robak

  • Martin Simkovic

  • Don Stevens

  • Sergey Voloshin

  • Vladimir Vorobyev

  • Munci Yagci

  • Loic Ysebaert

  • Rui Qin

  • Sriram Balasubramanian

  • Natasha Schuier

  • Kurt Baeten

  • Donne Bennett Caces

  • Carsten Niemann

Medical Centers

  • Tom Baker Cancer Center, Calgary, AB, Canada

  • Institut Universitaire du Cancer de Toulouse, Toulouse, France

  • Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

  • NSGO & Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark

  • Oncology,Norton Cancer Institute,Louisville,United States

  • Russian Scientific and Research Institute of Hematology and Transfusiology,Saint-Petersburg,Russian Federation

  • Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland

  • S P Botkin City Clinical Hospital,Moscow,Russie, Fédération De

  • Development,Beerse,Belgio

  • St James Hospital, Leeds, United Kingdom

  • Development,Düsseldorf,Germany

  • Ankara Universitesi Tip Fakultesi, Ankara, Turkey

  • Karolinska University Hospital, Stockholm, Sweden

  • Development,San Diego,United States

  • Janssen Research &amp

  • Development,Raritan,United States

  • University Hospital Hradec Kralove, Hradec Kralove, Czech Republic

  • Sheba Medical Center, Ramat-Gan, Ireland

  • Addenbrookes Hospital, Cambridge, United Kingdom

  • Hospital Santa Creu i Sant Pau, Barcelona, Spain

  • Albert Schweitzer Hospital, Dordrecht, Netherlands

  • UZ Leuven-Gasthuisberg, Leuven, Belgium

Locations

  • Canada

  • France

  • Netherlands

  • Denmark

  • United States

  • Russia

  • Poland

  • Belgium

  • United Kingdom

  • Germany

  • Turkey

  • Sweden

  • Czech Republic

  • Israel

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Chronic Lymphocytic Leukemia

  • Global developmental delay, lung cysts, overgrowth, and Wilms tumor

Biomarkers

  • Creatinine

  • Immunoglobulin heavy-chain variable region gene

  • Tumor protein p53

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • chlorambucil

  • Venetoclax

  • Ibrutinib

  • TP53

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03462719

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved